Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KIF18A | Q8NI77 | 9/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23981784 | 0.84 | PAX8 (0.41) | TSHRALDH1A1HTTLMNAMEN1 | |
| SCHEMBL614332 | 0.83 | PAX8 (0.43) | TSHRALDH1A1HTTLMNAMEN1 | |
| SCHEMBL22148386 | 0.82 | FFAR4 (0.54) | FFAR4TSHRHTTKIF18AMEN1 | |
| SCHEMBL26151048 | 0.78 | FFAR4 (0.48) | FFAR4KIF18ALMNAMEN1KMT2A | |
| SCHEMBL22282364 | 0.77 | FFAR4 (0.52) | FFAR4TSHRHTTMEN1KMT2A | |
| SCHEMBL31299031 | 0.72 | KDM4E (0.50) | FFAR4TSHRALDH1A1HTTKIF18A | |
| SCHEMBL23981588 | 0.71 | PAX8 (0.44) | TSHRALDH1A1HTTLMNAMEN1 | |
| SCHEMBL6648664 | 0.70 | FFAR4 (0.45) | FFAR4TSHRHTTLMNAMEN1 | |
| SCHEMBL22148758 | 0.69 | KIF18A (0.59) | KIF18A | |
| SCHEMBL24227047 | 0.69 | KDM4E (0.43) | TSHRHTTKIF18AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021211549-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2021-10-21 | — | — | WO | disclosed |